Differential activity of candidate microbicides against early steps of HIV-1 infection upon complement virus opsonization

AIDS Research and Therapy

Volumn 7, Issue , 2010, Pages

  Jenabian, Mohammad Ali ^a   Saïdi, Héla ^a   Charpentier, Charlotte ^a   Bouhlal, Hicham ^b   Schols, Dominique ^c   Balzarini, Jan ^c   Bell, Thomas W ^d   Vanham, Guido ^e   Bélec, Laurent ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

^c REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^d UNIVERSITY OF NEVADA   (United States)

^e INSTITUTE OF TROPICAL MEDICINE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; COMPLEMENT; CYCLOTRIAZADISULFONAMIDE; ENFUVIRTIDE; GLYCOPROTEIN GP 160 ANTIBODY; LACTOFERRIN; LECTIN DERIVATIVE; MANNAN ANTIBODY; MICROBICIDE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 12G5; MONOCLONAL ANTIBODY 2F5; MONOCLONAL ANTIBODY 2G12; MONOCLONAL ANTIBODY 2G5; MONOCLONAL ANTIBODY IMMUNOGLOBULIN G 1B12; PLANT LECTIN; POLYCLONAL ANTIBODY; SULFATED POLYVINYL ALCOHOL; UNCLASSIFIED DRUG;

ADSORPTION; ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; DRUG MECHANISM; EPITHELIUM CELL; GALANTHUS; GALANTHUS NIVALIS; HIPPEASTRUM HYBRID; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VITRO STUDY; MEDICINAL PLANT; MONOCYTE; NONHUMAN; OPSONIZATION; PRIORITY JOURNAL; TARGET CELL; TRANSCYTOSIS; VIRUS CELL INTERACTION; VIRUS INFECTIVITY;

EID: 77953340873     PISSN: 17426405     EISSN: None     Source Type: Journal    
DOI: 10.1186/1742-6405-7-16     Document Type: Article

References (41)

1. Feldblum PJ, Adeiga A, Bakare R, Wevill S, Lendvay A, Obadaki F, Olayemi MO, Wang L, Nanda K, Rountree W. SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria. PloS one 2008, 3(1):e1474. 10.1371/journal.pone.0001474, 2190795, 18213382.
2. Van Damme L, Govinden R, Mirembe FM, Guedou F, Solomon S, Becker ML, Pradeep BS, Krishnan AK, Alary M, Pande B, et al. Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. The New England journal of medicine 2008, 359(5):463-472. 10.1056/NEJMoa0707957, 18669425.
3. Saidi H, Jenabian MA, Bélec L. Early events in vaginal HIV transmission: Implications in microbicide development. Future Virol 2009, 4(3):259-269.
4. Ying H, Ji X, Hart ML, Gupta K, Saifuddin M, Zariffard MR, Spear GT. Interaction of mannose-binding lectin with HIV type 1 is sufficient for virus opsonization but not neutralization. AIDS research and human retroviruses 2004, 20(3):327-335. 10.1089/088922204322996563, 15117456.
5. Royce RA, Sena A, Cates W, Cohen MS. Sexual transmission of HIV. The New England journal of medicine 1997, 336(15):1072-1078. 10.1056/NEJM199704103361507, 9091805.
6. Shepard RN, Schock J, Robertson K, Shugars DC, Dyer J, Vernazza P, Hall C, Cohen MS, Fiscus SA. Quantitation of human immunodeficiency virus type 1 RNA in different biological compartments. Journal of clinical microbiology 2000, 38(4):1414-1418. 86455, 10747117.
7. Neurath AR, Strick N, Li YY. Role of seminal plasma in the anti-HIV-1 activity of candidate microbicides. BMC infectious diseases 2006, 6:150. 10.1186/1471-2334-6-150, 1618840, 17042959.
8. Stoiber H, Speth C, Dierich MP. Role of complement in the control of HIV dynamics and pathogenesis. Vaccine 2003, 21(Suppl 2):S77-82. 10.1016/S0264-410X(03)00203-2, 12763687.
9. Rahimi A, Sepehri H, Pakravesh J, Bahar K. Quantification of C3 and C4 in infertile men with antisperm antibody in their seminal plasma. Am J Reprod Immunol 1999, 41(5):330-336.
10. Stoiber H, Banki Z, Wilflingseder D, Dierich MP. Complement-HIV interactions during all steps of viral pathogenesis. Vaccine 2008, 26(24):3046-3054. 10.1016/j.vaccine.2007.12.003, 18191309.
11. Vanderpuye OA, Labarrere CA, McIntyre JA. The complement system in human reproduction. Am J Reprod Immunol 1992, 27(3-4):145-155.
12. Bouhlal H, Chomont N, Haeffner-Cavaillon N, Kazatchkine MD, Belec L, Hocini H. Opsonization of HIV-1 by semen complement enhances infection of human epithelial cells. J Immunol 2002, 169(6):3301-3306.
13. Bouhlal H, Chomont N, Requena M, Nasreddine N, Saidi H, Legoff J, Kazatchkine MD, Belec L, Hocini H. Opsonization of HIV with complement enhances infection of dendritic cells and viral transfer to CD4 T cells in a CR3 and DC-SIGN-dependent manner. J Immunol 2007, 178(2):1086-1095.
14. Saidi H, Eslahpazir J, Carbonneil C, Carthagena L, Requena M, Nassreddine N, Belec L. Differential modulation of human lactoferrin activity against both R5 and X4-HIV-1 adsorption on epithelial cells and dendritic cells by natural antibodies. J Immunol 2006, 177(8):5540-5549.
15. Ball JM, Moldoveanu Z, Melsen LR, Kozlowski PA, Jackson S, Mulligan MJ, Mestecky JF, Compans RW. A polarized human endometrial cell line that binds and transports polymeric IgA. In vitro cellular & developmental biology 1995, 31(3):196-206.
16. Van Damme EJAA, Peumans WJ. Related mannose-specific lectins from different species of the family Amaryllidaceae. Physiol Plant 1988, 73:52-57.
17. Baba M, Schols D, De Clercq E, Pauwels R, Nagy M, Gyorgyi-Edelenyi J, Low M, Gorog S. Novel sulfated polymers as highly potent and selective inhibitors of human immunodeficiency virus replication and giant cell formation. Antimicrobial agents and chemotherapy 1990, 34(1):134-138. 171534, 2327749.
18. Berkhout B, Floris R, Recio I, Visser S. The antiviral activity of the milk protein lactoferrin against the human immunodeficiency virus type 1. Biometals 2004, 17(3):291-294. 10.1023/B:BIOM.0000027707.82911.be, 15222480.
19. Vermeire K, Brouwers J, Van Herrewege Y, Le Grand R, Vanham G, Augustijns P, Bell TW, Schols D. CADA, a potential anti-HIV microbicide that specifically targets the cellular CD4 receptor. Current HIV research 2008, 6(3):246-256. 10.2174/157016208784324958, 18473788.
20. Bouhlal H, Galon J, Kazatchkine MD, Fridman WH, Sautes-Fridman C, Haeffner Cavaillon N. Soluble CD16 inhibits CR3 (CD11b/CD18)-mediated infection of monocytes/macrophages by opsonized primary R5 HIV-1. J Immunol 2001, 166(5):3377-3383.
21. Hocini H, Becquart P, Bouhlal H, Chomont N, Ancuta P, Kazatchkine MD, Belec L. Active and selective transcytosis of cell-free human immunodeficiency virus through a tight polarized monolayer of human endometrial cells. Journal of virology 2001, 75(11):5370-5374. 10.1128/JVI.75.11.5370-5374.2001, 114943, 11333919.
22. Stoiber H, Frank I, Spruth M, Schwendinger M, Mullauer B, Windisch JM, Schneider R, Katinger H, Ando I, Dierich MP. Inhibition of HIV-1 infection in vitro by monoclonal antibodies to the complement receptor type 3 (CR3): an accessory role for CR3 during virus entry?. Molecular immunology 1997, 34(12-13):855-863. 10.1016/S0161-5890(97)00108-9, 9464521.
23. Thieblemont N, Delibrias C, Fischer E, Weiss L, Kazatchkine MD, Haeffner-Cavaillon N. Complement enhancement of HIV infection is mediated by complement receptors. Immunopharmacology 1993, 25(2):87-93. 10.1016/0162-3109(93)90012-F, 8500986.
24. Banki Z, Stoiber H, Dierich MP. HIV and human complement: inefficient virolysis and effective adherence. Immunology letters 2005, 97(2):209-214. 10.1016/j.imlet.2004.11.007, 15752560.
25. Pinter C, Siccardi AG, Lopalco L, Longhi R, Clivio A. HIV glycoprotein 41 and complement factor H interact with each other and share functional as well as antigenic homology. AIDS research and human retroviruses 1995, 11(8):971-980. 10.1089/aid.1995.11.971, 7492444.
26. Schmitz J, Zimmer JP, Kluxen B, Aries S, Bogel M, Gigli I, Schmitz H. Antibody-dependent complement-mediated cytotoxicity in sera from patients with HIV-1 infection is controlled by CD55 and CD59. The Journal of clinical investigation 1995, 96(3):1520-1526. 10.1172/JCI118190, 185777, 7544808.
27. Stoiber H, Ammann C, Spruth M, Mullauer B, Eberhart A, Harris CL, Huber CG, Longhi R, Falkensammer B, Wurzner R, et al. Enhancement of complement-mediated lysis by a peptide derived from SCR 13 of complement factor H. Immunobiology 2001, 203(4):670-686.
28. Stoiber H, Pinter C, Siccardi AG, Clivio A, Dierich MP. Efficient destruction of human immunodeficiency virus in human serum by inhibiting the protective action of complement factor H and decay accelerating factor (DAF, CD55). The Journal of experimental medicine 1996, 183(1):307-310. 10.1084/jem.183.1.307, 2192395, 8551237.
29. Takefman DM, Sullivan BL, Sha BE, Spear GT. >Mechanisms of resistance of HIV-1 primary isolates to complement-mediated lysis. Virology 1998, 246(2):370-378. 10.1006/viro.1998.9205, 9657955.
30. Stone A. Microbicides: a new approach to preventing HIV and other sexually transmitted infections. Nature reviews 2002, 1(12):977-985. 10.1038/nrd959, 12461519.
31. Balzarini J. Targeting the glycans of glycoproteins: a novel paradigm for antiviral therapy. Nat Rev Microbiol 2007, 5(8):583-597. 10.1038/nrmicro1707, 17632570.
32. Balzarini J, Hatse S, Vermeire K, Princen K, Aquaro S, Perno CF, De Clercq E, Egberink H, Vanden Mooter G, Peumans W, et al. Mannose-specific plant lectins from the Amaryllidaceae family qualify as efficient microbicides for prevention of human immunodeficiency virus infection. Antimicrobial agents and chemotherapy 2004, 48(10):3858-3870. 10.1128/AAC.48.10.3858-3870.2004, 521907, 15388446.
33. Saidi H, Magri G, Nasreddine N, Requena M, Belec L. R5- and X4-HIV-1 use differentially the endometrial epithelial cells HEC-1A to ensure their own spread: implication for mechanisms of sexual transmission. Virology 2007, 358(1):55-68. 10.1016/j.virol.2006.07.029, 16934308.
34. Vives RR, Imberty A, Sattentau QJ, Lortat-Jacob H. Heparan sulfate targets the HIV-1 envelope glycoprotein gp120 coreceptor binding site. The Journal of biological chemistry 2005, 280(22):21353-21357. 10.1074/jbc.M500911200, 15797855.
35. June RA, Schade SZ, Bankowski MJ, Kuhns M, McNamara A, Lint TF, Landay AL, Spear GT. Complement and antibody mediate enhancement of HIV infection by increasing virus binding and provirus formation. AIDS (London, England) 1991, 5(3):269-274.
36. Geijtenbeek TB, Kwon DS, Torensma R, van Vliet SJ, van Duijnhoven GC, Middel J, Cornelissen IL, Nottet HS, KewalRamani VN, Littman DR, et al. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 2000, 100(5):587-597. 10.1016/S0092-8674(00)80694-7, 10721995.
37. Requena M, Bouhlal H, Nasreddine N, Saidi H, Gody JC, Aubry S, Gresenguet G, Kazatchkine MD, Sekaly RP, Belec L, et al. Inhibition of HIV-1 transmission in trans from dendritic cells to CD4+ T lymphocytes by natural antibodies to the CRD domain of DC-SIGN purified from breast milk and intravenous immunoglobulins. Immunology 2008, 123(4):508-518. 10.1111/j.1365-2567.2007.02717.x, 2433318, 17999675.
38. Saidi H, Magri G, Carbonneil C, Nasreddine N, Requena M, Belec L. >IFN-gamma-activated monocytes weakly produce HIV-1 but induce the recruitment of HIV-sensitive T cells and enhance the viral production by these recruited T cells. Journal of leukocyte biology 2007, 81(3):642-653. 10.1189/jlb.0406278, 16971466.
39. Legrand D, Vigie K, Said EA, Elass E, Masson M, Slomianny MC, Carpentier M, Briand JP, Mazurier J, Hovanessian AG. Surface nucleolin participates in both the binding and endocytosis of lactoferrin in target cells. European journal of biochemistry/FEBS 2004, 271(2):303-317. 10.1046/j.1432-1033.2003.03929.x, 14717698.
40. Nisole S, Said EA, Mische C, Prevost MC, Krust B, Bouvet P, Bianco A, Briand JP, Hovanessian AG. The anti-HIV pentameric pseudopeptide HB-19 binds the C-terminal end of nucleolin and prevents anchorage of virus particles in the plasma membrane of target cells. The Journal of biological chemistry 2002, 277(23):20877-20886. 10.1074/jbc.M110024200, 11919179.
41. Margolis L, Shattock R. Selective transmission of CCR5-utilizing HIV-1: the 'gatekeeper' problem resolved?. Nat Rev Microbiol 2006, 4(4):312-317. 10.1038/nrmicro1387, 16541138.